Earnings Feed
Start Free
Home/Filings/4/0000929638-25-002234
4//SEC Filing

Cormorant Asset Management, LP 4

Accession 0000929638-25-002234

CIK 0001840439other
View on SEC.govCompany Profile

Filed

Jun 12, 8:00 PM ET

Accepted

Jun 13, 4:02 PM ET

Size

17.5 KB

Accession

0000929638-25-002234

Insider Transaction Report

Form 4
Period: 2025-06-11
Biomea Fusion, Inc.BMEA
Chen Bihua
Director10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-06-11+91,970→ 91,970 total
    Exercise: $2.50Exp: 2035-06-10→ Common Stock (91,970 underlying)
Holdings

  • Stock Option (right to buy)

    Exercise: $38.90Exp: 2033-06-13→ Common Stock (6,989 underlying)
    6,989

  • Stock Option (right to buy)

    Exercise: $10.20Exp: 2032-06-21→ Common Stock (23,867 underlying)
    23,867

  • Stock Option (right to buy)

    Exercise: $4.63Exp: 2034-06-11→ Common Stock (51,025 underlying)
    51,025

  • Common Stock

    (indirect: See Footnotes)
    3,570,872

  • Stock Option (right to buy)

    Exercise: $17.00Exp: 2031-04-14→ Common Stock (28,911 underlying)
    28,911
Cormorant Global Healthcare Master Fund, LP
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-06-11+91,970→ 91,970 total
    Exercise: $2.50Exp: 2035-06-10→ Common Stock (91,970 underlying)
Holdings

  • Common Stock

    (indirect: See Footnotes)
    3,570,872

  • Stock Option (right to buy)

    Exercise: $17.00Exp: 2031-04-14→ Common Stock (28,911 underlying)
    28,911

  • Stock Option (right to buy)

    Exercise: $4.63Exp: 2034-06-11→ Common Stock (51,025 underlying)
    51,025

  • Stock Option (right to buy)

    Exercise: $10.20Exp: 2032-06-21→ Common Stock (23,867 underlying)
    23,867

  • Stock Option (right to buy)

    Exercise: $38.90Exp: 2033-06-13→ Common Stock (6,989 underlying)
    6,989
Cormorant Private Healthcare Fund III LP
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-06-11+91,970→ 91,970 total
    Exercise: $2.50Exp: 2035-06-10→ Common Stock (91,970 underlying)
Holdings

  • Stock Option (right to buy)

    Exercise: $10.20Exp: 2032-06-21→ Common Stock (23,867 underlying)
    23,867

  • Stock Option (right to buy)

    Exercise: $4.63Exp: 2034-06-11→ Common Stock (51,025 underlying)
    51,025

  • Stock Option (right to buy)

    Exercise: $17.00Exp: 2031-04-14→ Common Stock (28,911 underlying)
    28,911

  • Stock Option (right to buy)

    Exercise: $38.90Exp: 2033-06-13→ Common Stock (6,989 underlying)
    6,989

  • Common Stock

    (indirect: See Footnotes)
    3,570,872
Cormorant Asset Management, LLC
10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-06-11+91,970→ 91,970 total
    Exercise: $2.50Exp: 2035-06-10→ Common Stock (91,970 underlying)
Holdings

  • Stock Option (right to buy)

    Exercise: $38.90Exp: 2033-06-13→ Common Stock (6,989 underlying)
    6,989

  • Stock Option (right to buy)

    Exercise: $10.20Exp: 2032-06-21→ Common Stock (23,867 underlying)
    23,867

  • Stock Option (right to buy)

    Exercise: $4.63Exp: 2034-06-11→ Common Stock (51,025 underlying)
    51,025

  • Common Stock

    (indirect: See Footnotes)
    3,570,872

  • Stock Option (right to buy)

    Exercise: $17.00Exp: 2031-04-14→ Common Stock (28,911 underlying)
    28,911
Footnotes (5)
  • [F1]Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP (the "Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  • [F2]Represents (i) 1,795,928 shares of Common Stock held by the Master Fund, (ii) 1,717,232 shares of Common Stock held by Fund III, and (iii) 57,712 shares of Common Stock held by the Account.
  • [F3]The options were granted with a 36 month vesting period, vesting monthly.
  • [F4]Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.
  • [F5]The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to Ms. Chen's continuing service to the Issuer through such vesting date.

Documents

1 file

Issuer

Biomea Fusion, Inc.

CIK 0001840439

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001583977

Filing Metadata

Form type
4
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 4:02 PM ET
Size
17.5 KB
View on SEC.gov